Is there real human data on NAD+?

Yes — randomised trials in Cell Metabolism, Science and GeroScience. All used precursors rather than NAD+ itself.

What did they measure?

Largely biomarkers and mechanism endpoints. Yoshino 2021 measured muscle insulin sensitivity, which is more physiological.

Is this strong evidence?

Real early-stage evidence, better than most of this catalogue. Not confirmatory — the trials are small and early-phase.

NAD+

What the Human Trials Actually Found

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

Randomised human data exists and is better than for most compounds in this catalogue — including trials published in Cell Metabolism, Science and GeroScience. Every one of them used a precursor rather than NAD+ itself, and the endpoints are largely biomarkers rather than clinical outcomes.

Key facts

NADPARK: Randomised phase I, NR, Parkinson's, Cell Metab 2022
Orr 2024: Randomised placebo-controlled, NR, older adults
Yoshino 2021: NMN, muscle insulin sensitivity, Science
Yi 2023: NMN efficacy and safety, GeroScience
Compound used: Precursors in all of them
Dominant endpoints: Biomarkers, not outcomes

NADPARK

Brakedal and colleagues published a randomised phase I trial of nicotinamide riboside supplementation in Parkinson's disease in Cell Metabolism in 2022. Phase I means the primary questions were safety and whether the intervention did what it was supposed to biologically — not whether it helped. Choosing Parkinson's reflects a specific mitochondrial hypothesis rather than a general ageing one.

Orr 2024

A randomised placebo-controlled trial of nicotinamide riboside in older adults, published in GeroScience in 2024. Placebo-controlled and randomised is the right design, and the population is the one the ageing hypothesis actually concerns. It is a real contribution, and it is modest in scale.

Research material referenced

NAD+ 500mg — third-party HPLC tested

View — £49.99

Yoshino 2021

Published in Science in 2021, reporting that nicotinamide mononucleotide increased muscle insulin sensitivity in prediabetic women. Publication in Science reflects a genuinely notable result, and the endpoint — insulin sensitivity — is more physiological than a simple NAD+ level. It is one trial in one specific population.

The pattern across all of them

Precursors, not NAD+. Biomarker and mechanism endpoints more than clinical outcomes. Modest sample sizes. Early phases. This is a field with real randomised evidence at an early stage — which is substantially better than most of this catalogue and substantially short of what the surrounding commentary implies.

What is conspicuously absent

Large trials with hard clinical endpoints. Nothing here resembles the scale of the incretin programmes — TRIUMPH enrolled over 5,800 participants across multiple Phase 3 studies. NAD+ precursor research has produced good early evidence, not confirmatory evidence, and the difference is not a technicality.

And none of it concerns NAD+ as supplied here

The trials administered defined precursor preparations under clinical supervision with ethics approval. Material supplied for laboratory research is not those preparations and is not covered by those findings.

Extended research context

The NAD+ deep dive

Deep dive: the compound in this catalogue that is not a peptide

NAD+ contains no amino acids and no peptide bonds. It is a dinucleotide - a nicotinamide nucleotide and an adenine nucleotide joined through a pyrophosphate bridge - which is the structural grammar of ATP and of RNA, not of a protein. It sits in a peptide catalogue because it reaches the same buyers, not because it belongs there. Saying so matters practically rather than pedantically: essentially all of the general handling guidance on this site is written for peptides and is the wrong guidance here. There is no sequence to verify, so purity by amino acid analysis is meaningless. There are no deletion sequences, because there is no stepwise coupling to produce them. Net peptide content, the figure that decides how much material a lyophilised peptide vial actually contains, has no analogue at all. Even the instruction that does carry over - dry, cold, dark - protects different chemistry, guarding glycosidic and pyrophosphate bonds rather than peptide bonds and methionine residues.

Deep dive: why the finished molecule is the least deliverable of the three

NAD+ carries two negatively charged phosphates and weighs 663.4 Da, and neither property is compatible with crossing a lipid bilayer. Extracellular NAD+ is also actively consumed: CD38 is an ectoenzyme with its active site facing outward, and Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive tissue NAD+ decline specifically by raising CD38 activity. Put those together and administered NAD+ is a molecule that cannot get in and is being degraded while it waits. Whatever follows most plausibly runs through its breakdown to smaller nicotinamide-containing species, which cells then take up and rebuild NAD+ from internally - which is to say, through exactly the precursors people otherwise take directly. This is why every substantial randomised trial in the field used nicotinamide riboside at 255.25 Da or nicotinamide mononucleotide at 334.22 Da rather than the coenzyme itself. The naming inverts the pharmacology: the finished molecule sounds like the most direct option and is the least.

Deep dive: good early evidence, and the gap that keeps getting closed rhetorically

The randomised human literature here is better than for most of this catalogue. NADPARK was a randomised phase I trial of nicotinamide riboside in Parkinson disease in Cell Metabolism. Orr and colleagues ran a randomised placebo-controlled study in older adults in GeroScience. Yoshino and colleagues published NMN and muscle insulin sensitivity in Science. These are real trials in real journals. What they measured, largely, is whether the intervention does what it is supposed to biologically - and raising a biomarker is not the same as changing an outcome. The step that gets taken rhetorically is from a decline that is real, through a mechanism that is identified, to a benefit that has not been demonstrated. Each link looks small; the chain is not. Nothing in this field approaches the scale of what settled the incretin questions, where TRIUMPH alone enrolled more than 5,800 participants with hard clinical endpoints.

Research applications

▸Cellular NAD+ metabolism and salvage pathway research
▸Sirtuin, PARP and CD38 enzyme activity studies
▸Redox biochemistry and NAD+/NADH ratio measurement
▸Cellular senescence and ageing biology research
▸Mitochondrial function and metabolic assay work
▸Comparative precursor uptake and conversion studies

Handling checklist

✓Verify against CID 5892, 663.4 Da, C21H27N7O14P2 - not by sequence
✓Do not apply peptide purity or net peptide content logic - neither exists here
✓Store lyophilised, cold, dry and protected from light
✓Prepare solutions fresh; nucleotide bonds hydrolyse readily in water
✓Be aware NAD+ and NADH are separately quantifiable oxidation states
✓Identity is confirmed by mass and chromatography against a reference standard

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Applying peptide handling and purity guidance to NAD+

Fix: It is a dinucleotide with no peptide bonds. Sequence verification, protease concerns, disulfide chemistry and net peptide content are all inapplicable.

✗ Assuming administered NAD+ enters cells intact

Fix: Two negative phosphate charges and 663 Da prevent membrane crossing, and CD38 degrades it extracellularly. Effects most plausibly run through breakdown products.

✗ Reading precursor trial results as evidence for NAD+ itself

Fix: Every substantial randomised trial used NR or NMN. NAD+ has essentially no comparable human literature.

✗ Treating a biomarker increase as a demonstrated benefit

Fix: Raising NAD+-related markers is reasonably supported. Durable clinical outcome data does not exist.

✗ Taking a precursor's food supplement status as evidence of efficacy

Fix: Supplement frameworks assess safety for consumption, not efficacy, and permit no therapeutic claims.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is there real human data on NAD+?: Yes — randomised trials in Cell Metabolism, Science and GeroScience. All used precursors rather than NAD+ itself.
What did they measure?: Largely biomarkers and mechanism endpoints. Yoshino 2021 measured muscle insulin sensitivity, which is more physiological.
Is this strong evidence?: Real early-stage evidence, better than most of this catalogue. Not confirmatory — the trials are small and early-phase.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More NAD+ articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum